Advertisement

Biomedical Microdevices

, 20:90 | Cite as

Proliferation arrest, selectivity, and chemosensitivity enhancement of cancer cells treated by a low-intensity alternating electric field

  • Kin Fong LeiEmail author
  • Shao-Chieh Hsieh
  • Andrew Goh
  • Rei-Lin Kuo
  • Ngan-Ming TsangEmail author
Article
  • 89 Downloads

Abstract

Elimination of serious side effects is a desired feature of cancer therapy. Alternating electric field treatment is one approach to the non-invasive treatment of cancer. The efficacy and safety of this novel therapy are confirmed for the treatment of glioblastoma multiforme. In the current study, we co-cultured cancer cells and normal cells to investigate the selectivity and chemosensitivity enhancement of an electric field treatment. Cancer cells (cell line: HeLa and Huh7) and fibroblasts (cell line: HEL299) were cultured in an in-house–developed cell culture device embedded with stimulating electrodes. A low-intensity alternating electric field was applied to the culture. The field significantly induced proliferation arrest of the cancer cells, while had limited influence on the fibroblasts. Moreover, in combination with the anti-cancer drug, damage to the cancer cells was enhanced by the electric field. Thus, a lower dosage of the drug could be applied to achieve the same treatment effectiveness. This study provides evidence that low-intensity electric field treatment selectively induced proliferation arrest and enhanced the chemosensitivity of the cancer cells. This electro-chemotherapy could be developed and applied as a regional cancer therapy with minimal side effects.

Keywords

Cancer therapy Cell culture Chemosensitivity Chemotherapy Electric field TTFields Tumor treating fields 

Notes

Acknowledgments

This work was supported by Chang Gung Memorial Hospital, Linkou, Taiwan (project numbers of CMRPD2G0172 and BMRPC05).

References

  1. D.N. Carney, J.B. Mitchell, T.J. Kinsella, In vitro radiation and chemotherapy sensitivity of established cell lines of human small cell lung cancer and its large cell morphological variants. Cancer Res. 43, 2806–2811 (1983)Google Scholar
  2. C.H. Chiu, K.F. Lei, W.L. Yeh, Development of a co-culture device for the study of human tenocytes in response to the combined stimulation of electric field and platelet-rich plasma (PRP). Biomed. Microdevices 19, 69 (2017)CrossRefGoogle Scholar
  3. R.A. El-Awady, M.H. Semrren, M.M. Saber-Ayad, F. Cyprian, V. Menon, T.H. Al-Tel, Modulation of DNA damage response and induction of apoptosis mediates synergism between doxorubicin and a new imidazopyridine derivative in breast and lung cancer cells. DNA Repair 37, 1–11 (2016)CrossRefGoogle Scholar
  4. A.M. Florea, D. Büsselberg, Cisplatin as an anti-tumor drug: Cellular mechanisms of activity, drug resistance and induced side effects. Cancers 3, 1351–1371 (2011)CrossRefGoogle Scholar
  5. T. Geng, C. Lu, Microfluidic electroporation for cellular analysis and delivery. Lab Chip 13, 3803–3821 (2013)CrossRefGoogle Scholar
  6. N. Gera, A. Yang, T.S. Holtzman, S.X. Lee, E.T. Wong, K.D. Swanson, Tumor treating fields perturb the localization of septins and cause aberrant mitotic exit. PLoS One 10, e125269 (2015)CrossRefGoogle Scholar
  7. M. Giladi, U. Weinberg, R.S. Schneiderman, Y. Porat, M. Munster, et al., Alternating electric fields (tumor-treating fields therapy) can improve chemotherapy treatment efficacy in non-small cell lung cancer both in vitro and in vivo. Semin. Oncol. 41, S35–S41 (2014)CrossRefGoogle Scholar
  8. M. Giladi, R.S. Schneiderman, T. Voloshin, Y. Porat, M. Munster, et al., Mitotic spindle disruption by alternating electric fields leads to improper chromosome segregation and mitotic catastrophe in cancer cells. Sci. Rep. 5, 18046 (2015)CrossRefGoogle Scholar
  9. C.W. Huang, J.Y. Cheng, M.H. Yen, T.H. Young, Electrotaxis of lung cancer cells in a multiple-electric-field chip. Biosens. Bioelectron. 24, 3510–3516 (2009)CrossRefGoogle Scholar
  10. T. Inui, H. Amitani, K. Kubo, D. Kuchiike, Y. Uto, T. Nishikata, M. Mette, Case report: A non-small cell lung cancer patient treated with GcMAF, sonodynamic therapy and tumor treating fields. Anticancer Res. 36, 3767–3770 (2016)Google Scholar
  11. C. Isanbor, D. O’Hagan, Fluorine in medicinal chemistry: A review of anti-cancer agents. J. Fluor. Chem. 127, 303–319 (2006)CrossRefGoogle Scholar
  12. E.D. Kirson, Z. Gurvich, R. Schneiderman, E. Dekel, A. Itzhaki, Y. Wasserman, R. Schatzberger, Y. Palti, Disruption of cancer cell replication by alternating electric fields. Cancer Res. 64, 3288–3295 (2004)CrossRefGoogle Scholar
  13. E.D. Kirson, V. Dbaly, F. Tovarys, J. Vymazal, J.F. Soustiel, et al., Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors. Proc. Natl. Acad. Sci. U. S. A. 104, 10152–10157 (2007)CrossRefGoogle Scholar
  14. E.D. Kirson, R.S. Schneiderman, V. Dbalý, F. Tovaryš, J. Vymazal, et al., Chemotherapeutic treatment efficacy and sensitivity are increased by adjuvant alternating electric fields (TTFields). BMC Med. Phys. 9(1) (2009)Google Scholar
  15. R.L. Kuo, L.H. Li, S.J. Lin, Z.H. Li, G.W. Chen, et al., Role of N terminus-truncated NS1 proteins of influenza a virus in inhibiting IRF3 activation. J. Virol. 90, 4696–4705 (2016)CrossRefGoogle Scholar
  16. K.F. Lei, I.C. Lee, Y.C. Liu, Y.C. Wu, Successful differentiation of neural stem/progenitor cells cultured on electrically adjustable indium tin oxide (ITO) surface. Langmuir 30, 14241–14249 (2014)CrossRefGoogle Scholar
  17. H. Lu, M.A. Schmidt, K.F. Jensen, A microfluidic electroporation device for cell lysis. Lab Chip 5, 23–29 (2005)CrossRefGoogle Scholar
  18. A.P. Mazzoieni, B.F. Sisken, R.L. Kahler, Conductivity values of tissue culture medium from 20 °C to 40 °C. Bioelectromagnetics 7, 95–99 (1986)CrossRefGoogle Scholar
  19. Y. Miki, K. Ono, S. Hata, T. Suzuki, H. Kumamoto, H. Sasano, The advantages of co-culture over mono cell culture in simulating in vivo environment. J. Steroid Biochem. Mol. Biol. 131, 68–75 (2012)CrossRefGoogle Scholar
  20. M. Pless, C. Drogege, R. von Moss, M. Salzberg, D. Betticher, A phase I/II trial of tumor treating fields (TTFields) therapy in combination with pemetrexed for advanced non-small cell lung cancer. Lung Cancer 81, 445–450 (2013)CrossRefGoogle Scholar
  21. A.M. Rulseh, J. Klener, J. Šroubek, V. Dbalý, M. Syrůček, F. Tovaryš, J. Vymazal, Long-term survival of patients suffering from glioblastoma multiforme treated with tumor-treating fields. World J. Surg. Oncol 10, 220 (2012)CrossRefGoogle Scholar
  22. R. Stupp, S. Taillbert, A.A. Kanner, S. Kesari, D.M. Steinberg, et al., Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma. JAMA 314, 2535–2543 (2015)CrossRefGoogle Scholar
  23. R. Stupp, S. Taillibert, A.A. Kanner, W. Read, D.M. Steinberg, et al., Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma. JAMA 318, 2306–2316 (2017)CrossRefGoogle Scholar
  24. O. Tacar, P. Sriamornask, C.R. Dass, Doxorubicin: An update on anticancer molecular action, toxicity and novel drug delivery systems. J. Pharm. Pharmacol. 65, 157–170 (2013)CrossRefGoogle Scholar
  25. J.L. Villano, L.E. Williams, K.S. Watson, N. Ignatius, M.T. Wilson, T. Valyi-Nagy, E.A. Michals, H.H. Engelhard, Delayed response and survival from NovoTTF-100A in recurrent GBM. Med. Oncol. 30, 338 (2013)CrossRefGoogle Scholar
  26. S. Wang, E.A. Konorev, S. Kotamraju, J. Joseph, S. Kalivendi, B. Kalyanaraman, Doxorubicin induces apoptosis in normal and tumor cells via distinctly different mechanisms. J. Biol. Chem. 279, 25535–25543 (2004)CrossRefGoogle Scholar
  27. C.C. Wang, Y.C. Kao, P.Y. Chi, C.W. Huang, J.Y. Lin, C.C. Chou, J.Y. Cheng, C.H. Lee, Asymmetric cancer-cell filopodium growth induced by electric-fields in a microfluidic culture chip. Lab Chip 11, 695–699 (2011)CrossRefGoogle Scholar
  28. J.C. Weaver, Y.A. Chizmadzhev, Theory of electroporation: A review. Bioelectrochem. Bioenerg. 41, 135–160 (1996)CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Graduate Institute of Biomedical EngineeringChang Gung UniversityTaoyuanTaiwan
  2. 2.Department of Radiation OncologyChang Gung Memorial HospitalLinkouTaiwan
  3. 3.Research Center for Emerging Viral Infections, College of MedicineChang Gung UniversityTaoyuanTaiwan
  4. 4.Graduate Institute of Biomedical SciencesChang Gung UniversityTaoyuanTaiwan
  5. 5.Department of Medical Biotechnology and Laboratory ScienceChang Gung UniversityTaoyuanTaiwan
  6. 6.Department of PediatricsChang Gung Memorial HospitalLinkouTaiwan
  7. 7.Department of Traditional Chinese MedicineChang Gung UniversityTaoyuanTaiwan

Personalised recommendations